Activity of CP 99,219 (trovafloxacin) compared with ciprofloxacin, sparfloxacin, clinafloxacin, lomefloxacin and cefuroxime against ten penicillin-susceptible and pencillin-resistant pneumococci by time-kill methodology

Journal of Antimicrobial Chemotherapy

Volumn 37, Issue 1, 1996, Pages 77-84

  Visalli, M A ^a   Jacobs, M R ^b   Appelbaum, P C ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFUROXIME; CIPROFLOXACIN; CLINAFLOXACIN; LOMEFLOXACIN; PENICILLIN G; SPARFLOXACIN; TROVAFLOXACIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STREPTOCOCCUS PNEUMONIAE;

ANTI-INFECTIVE AGENTS; CEFUROXIME; CIPROFLOXACIN; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; NAPHTHYRIDINES; PENICILLIN RESISTANCE; QUINOLONES; STREPTOCOCCUS PNEUMONIAE;

EID: 0029943752     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/37.1.77     Document Type: Article

References (21)

1. Appelbaum, P. C. (1992). Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clinical Infectious Diseases 15, 77-83.
2. Block, S., Hedrick, J., Wright, P., Finger, R., Leggiadro, R., Appleton, M. et al. (1994). Drug-resistant Streptococcus pneumoniae - Kentucky and Tenessee, 1993. Morbidity and Mortality Weekly Report 43, 23-5.
3. Breiman, R. F., Butler, J. C. Tenover, F. C., Elliott, J. A. & Facklam, R. R. (1994). Emergence of drug-resistant pneumococcal infections in the United States. Journal of the American Medical Association 271, 1831-5.
4. Cohen, M. A., Huband, M. D., Mailloux, G. B., Yoder, S. L., Roland, G. E. & Heifetz, C. L. (1991). In vitro antibacterial activities of the fluoroquinolones PD 117596, PD 124816, and PD 127391. Diagnostic Microbiology and Infectious Diseases 14, 245-58.
5. Eliopoulos, G. M., Klimm, K., Eliopoulos, C. T., Ferraro, M. J. & Moellering, R. C. (1993). In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of Gram-positive bacteria. Antimicrobial Agents and Chemotherapy, 37, 366-70.
6. Friedland, I. R. & McCracken, G. H. (1994). Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. New England Journal of Medicine 331, 377-82.
7. Friedland, I. R., Paris, M., Eherett, S., Mickey, S., Olsen, K. & McCracken, G. H. (1993). Evaluation of antimicrobial regimens for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrobial Agents and Chemotherapy 37, 1630-6.
8. Gootz, T. D., Brighty, K. E., Anderson, M. R., Schmieder, B. J., Haskell, S. L., Sutcliffe, J. A et al. (1994). In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl)naphthyridone antimicrobial. Diagnostic Microbiology and Infectious Diseases 19, 235-43.
9. Jacobs, M. R. (1992). Treatment and diagnosis of infections caused by drug-resistant Streptococcus pneumoniae. Clinical Infectious Diseases 15, 119-27.
10. King, A., Boothman, C. & Phillips, I. (1988). The in-vitro activity of PD 127,391, a new quinolone. Journal of Antimicrobial Chemotherapy 22, 135-41.
11. Munoz, R., Musser, J. M., Crain, M., Briles, D. E., Marton, A., Parkinson, A. J et al. (1992). Geographic distribution of penicillin-resistant clones of Streptococcus pneumoniae: characterization by penicillin-binding protein profile, surface protein A typing, and multilocus enzyme analysis. Clinical Infectious Diseases 15, 112-8.
12. National Committee for Clinical Laboratory Standards. (1993). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. Approved Standard M7-A3. NCCLS, Villanova, PA.
13. Neu, H. C. & Chin, N. X. (1994). In vitro activity of the new fluoroquinolone CP-99,219. Antimicrobial Agents and Chemotherapy 38, 2615-22.
14. Pankuch, G. A., Jacobs, M. R. & Appelbaum, P. C. (1994). Study of comparative antipneumococcal activities of penicillin G. RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology. Antimicrobial Agents and Chemotherapy 38, 2065-72.
15. Pankuch, G. A., Jacobs. M. R. & Appelbaum, P. C. (1995). Activity of CP 99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci. Journal of Antimicrobial Chemotherapy 35, 230-2.
16. Piddock, L. J. V. (1994). New quinolones and gram positive bacteria. Antimicrobial Agents and Chemotherapy 38, 163-9.
17. Spangler, S. K., Jacobs, M. R. & Appelbaum, P. C. (1992). Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin. Win 57273, ofloxacin and ciprofloxacin. Antimicrobial Agents and Chemotherapy 36, 856-9.
18. Spangler, S. K., Jacobs, M. R. & Appelbaum, P. C (1994). Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes. Antimicrobial Agents and Chemotherapy 38, 2471-6.
19. Spangler, S. K., Jacobs, M. R., Pankuch, G. A. & Appelbaum, P. C. (1993). Susceptibility of 170 penicillin-susceptible and -resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, RO 23-9424 and RP 67829. Journal of Antimicrobial Chemotherapy 31, 273-80.
20. Visalli, M. A., Jacobs, M. R. & Appelbaum, P. C. (1995). Antipneumococcal activity of seven oral β-lactams by time-kill methodology. In Program and Abstracts of the Ninety-Fifth Annual Meeting of the American Society for Microbiology, Washington, DC, 1995. Abstract A-2, p. 144. American Society for Microbiology, Washington, DC.
21. Wise, R., Ashby, J. P. & Andrews, J. M. (1988). In vitro activity of PD 127,391, an enhanced-spectrum quinolone. Antimicrobial Agents and Chemotherapy 32, 1251-6.